Veritas Genetics to Close Its Testing Operations in U.S.

By Joseph Burns

MAYBE CHARGING CONSUMERS THE LOW PRICE of $599 for a whole human genome sequence is not a winning financial strategy. That’s one possible reason why closely-watched Veritas Genetics of Cambridge, Mass., will stop operations in the United States. It was in July that Veritas annou…

Read More

---

How Labs Can Add Value for Providers, Insurers, Pharma

By Joseph Burns | From the Volume XXVI No. 15 – November 4, 2019 Issue

CEO SUMMARY: For pathologists and clinical, molecular, and genetic testing labs, appropriate reuses of lab data can provide a new source of revenue. Labs that serve as preferred providers of diagnostic testing data can help health systems, ordering physicians, pharmaceutical companies, an…

Read More

---

DOJ Charges 35 Individuals In Genetic Testing Scam

By Joseph Burns | From the Volume XXVI No. 14 – October 14, 2019 Issue

CEO SUMMARY: Federal prosecutors said those charged illegally lured elderly patients nationwide into giving cheek swabs for fraudulent genetic tests. The indicted individuals allegedly paid kickbacks and bribes to medical professionals working with telemedicine companies in exchange for r…

Read More

---

March 18, 2019 Intelligence: Late Breaking Lab News

By Robert Michel | From the Volume XXVI No. 4 – March 18, 2019 Issue

Because of a $25 million grant from philanthropist Denny Sanford, the Veterans Administration and Sanford Health will provide free genetic testing to 250,000 veterans by 2022. These will be pharmacogenomic (PGx) tests designed to help VA physicians prescribe medicat…

Read More

---

U of Florida Health Improves Patient Care with PGx Testing

By Joseph Burns | From the Volume XXV No. 17 – December 3, 2018 Issue

CEO SUMMARY: Since 2011, the University of Florida Health System has used pharmacogenetic test (PGx) results to guide physicians when they prescribe certain drugs. This initiative has improved patient outcomes, reduced the overall cost per episode of care, and gained partial reimbursemen…

Read More

---

Illumina to Pay $1.2 Billion to Acquire Pacific Biosciences

By Joseph Burns | From the Volume XXV No. 17 – December 3, 2018 Issue

IT’S AN ACQUISITION THAT BRINGS TOGETHER two different gene sequencing technologies into one firm. On Nov. 1, Illumina, Inc., announced an agreement to acquire Pacific Biosciences (PacBio) for $1.2 billion. This deal will bolster Illumina’s already-dominant posit…

Read More

---

Coming Soon to a Doctor’s Office Near You!

By R. Lewis Dark | From the Volume XXV No. 10 – July 9, 2018 Issue

IT’S TIME FOR ALL CLINICAL LABS AND ANATOMIC PATHOLOGY GROUPS to pay closer attention to the advances in genetic medicine and precision medicine. Events are moving even faster than most experts have predicted. As you will read on pages 3-4, two innovative health networks are on the verge of offeri…

Read More

---

LAB BRIEFS

By Robert Michel | From the Volume XXV No. 4 – March 5, 2018 Issue

DUBAI TO TEST DNA OF ITS 3 MILLION CITIZENS RECENTLY, GOVERNMENT OFFICIALS in Dubai announced a plan to conduct genetic testing on all three million residents. Experts say this is an unprecedented decision by any national govern…

Read More

---

Cautious Optimism Seen At Dark Report’s Executive War College

By Mary Van Doren | From the Volume XXIV No. 7 – May 15, 2017 Issue

This is an excerpt from an 850-word article in the May 15, 2017, issue of THE DARK REPORT. The complete article is available for a limited time to all readers, and available at all times to paid members of the Dark Intelligence Group. CEO SUMMARY: There…

Read More

---

Cautious Optimism Seen At Executive War College

By Robert Michel | From the Volume XXIV No. 7 – May 15, 2017 Issue

CEO SUMMARY: Among the major themes to emerge from the more than 60 sessions and 100 speakers at this year’s Executive War College on Lab and Pathology Management were the accelerating pace of integrated care, the growth of precision medicine, and use of big data to guide physicians. Ot…

Read More

---